Moss 16.06.2020

Gentian Diagnostics is pleased to announce the release of the new CE marked
turbidimetric immunoassay for the simplified quantification of human pancreatic
elastase, helping to monitor Pancreatic Exocrine Insufficiency (PEI), the
BÜHLMANN fPELA® turbo. This assay is sold through Gentian’s partner BÜHLMANN and
Gentian is the sole reagent provider and manufacturer.

BÜHLMANN fPELA® turbo, an immuno turbidimetric faecal pancreatic elastase assay,
provides flexible and random-access application on most available clinical
chemistry platforms. The assay reduces hands-on time required dramatically and
allows the pancreatic elastase results from human stool samples to be reported
in a short time. 
The same extraction buffer for pancreatic elastase and faecal calprotectin,
BÜHLMANN fCAL® turbo, allows the quantitation of both analytes from the same
sample preparation. This helps improve diagnostic efficiency, in addition to
clinical advantage, as inflammatory bowel disease (IBD) increases risk for PEI
and IBD/PEI symptoms overlap. 

Gentian has, in cooperation with BÜHLMANN, delivered the BÜHLMANN fCAL® turbo to
the market successfully since 2016. The BÜHLMANN fCAL® turbo is the most
automated IVD test system for IBD on the market. It enables laboratories to
provide results faster to their clinicians and to run higher test volumes, based
on the increasing demand for IBD laboratory diagnostic solutions.

Gentian´s CEO Dr. Hilja Ibert says: As part of the fruitful partnership with
BÜHLMANN Laboratories AG, I’m very excited to see the market introduction of the
BÜHLMANN fPELA® turbo as a valuable supplement to the existing BÜHLMANN fCAL®
turbo.


For further information, please contact:


Hilja Ibert

CEO, Gentian Diagnostics

E-mail: hilja.ibert@gentian.no

Cell Phone: +47 919 05 242



Njaal Kind

CFO, Gentian Diagnostics

E-mail: njaal.kind@gentian.no

Cell Phone. +47 919 06 525